Introduction:
The global biosimilars market is experiencing significant growth, driven by increasing demand for cost-effective alternatives to biologic drugs. According to recent market research, the biosimilars market is expected to reach $35 billion by 2026. In this report, we will explore the top 20 biosimilars collaboration deals worldwide that are shaping the industry landscape.
Top 20 Biosimilars Collaboration Deals Worldwide 2026:
1. Pfizer and BioNTech – Pfizer and BioNTech have collaborated on the development and production of biosimilar versions of several blockbuster drugs, including Humira and Rituxan. This collaboration has helped both companies expand their presence in the biosimilars market.
2. Samsung Bioepis and Biogen – Samsung Bioepis and Biogen have partnered to develop and commercialize biosimilars for multiple therapeutic areas, such as oncology and immunology. This collaboration has enabled both companies to leverage their expertise and resources to bring high-quality biosimilars to market.
3. Sandoz and Momenta Pharmaceuticals – Sandoz, a division of Novartis, and Momenta Pharmaceuticals have joined forces to develop biosimilar versions of key biologic drugs. This partnership has strengthened Sandoz’s position in the biosimilars market and enhanced Momenta’s capabilities in biosimilar development.
4. Mylan and Biocon – Mylan and Biocon have established a successful collaboration to develop and market biosimilars for global markets. This partnership has enabled both companies to expand their biosimilars portfolios and reach a wider patient population.
5. Teva Pharmaceutical Industries and Celltrion – Teva Pharmaceutical Industries and Celltrion have teamed up to develop biosimilars for various therapeutic areas, including oncology and autoimmune diseases. This collaboration has enhanced both companies’ competitiveness in the biosimilars market.
6. Amgen and Allergan – Amgen and Allergan have formed a strategic collaboration to develop and commercialize biosimilar versions of several biologic drugs. This partnership has allowed both companies to capitalize on their strengths in biologic drug development and expand their biosimilars offerings.
7. Boehringer Ingelheim and AbbVie – Boehringer Ingelheim and AbbVie have entered into a partnership to develop biosimilars for multiple indications, such as rheumatoid arthritis and psoriasis. This collaboration has enabled both companies to enhance their biosimilars pipelines and compete more effectively in the market.
8. Merck & Co. and Samsung Bioepis – Merck & Co. and Samsung Bioepis have collaborated on the development and commercialization of biosimilars for various therapeutic areas. This partnership has helped both companies leverage their expertise and resources to bring high-quality biosimilars to patients worldwide.
9. Fresenius Kabi and mAbxience – Fresenius Kabi and mAbxience have joined forces to develop and market biosimilars for global markets. This collaboration has enabled both companies to expand their biosimilars portfolios and provide affordable treatment options to patients.
10. Lupin and Mylan – Lupin and Mylan have partnered to develop and commercialize biosimilars for multiple indications, such as diabetes and oncology. This collaboration has strengthened Lupin’s presence in the biosimilars market and enhanced Mylan’s capabilities in biosimilar development.
11. Dr. Reddy’s Laboratories and Cipla – Dr. Reddy’s Laboratories and Cipla have established a successful collaboration to develop biosimilar versions of key biologic drugs. This partnership has enabled both companies to expand their biosimilars portfolios and reach a wider patient population.
12. Celltrion and Hospira – Celltrion, a leading biopharmaceutical company, has partnered with Hospira to develop and commercialize biosimilars for various therapeutic areas. This collaboration has enhanced both companies’ competitiveness in the biosimilars market and provided patients with affordable treatment options.
13. Biocon and Mylan – Biocon and Mylan have formed a strategic collaboration to develop and commercialize biosimilar versions of several biologic drugs. This partnership has allowed both companies to capitalize on their strengths in biologic drug development and expand their biosimilars offerings.
14. Amgen and Pfizer – Amgen and Pfizer have collaborated on the development and production of biosimilar versions of several blockbuster drugs, including Enbrel and Neulasta. This collaboration has helped both companies expand their presence in the biosimilars market.
15. Novartis and Sandoz – Novartis and Sandoz, a division of Novartis, have teamed up to develop biosimilars for various therapeutic areas, such as oncology and autoimmune diseases. This collaboration has enhanced both companies’ competitiveness in the biosimilars market.
16. Teva Pharmaceutical Industries and Celltrion – Teva Pharmaceutical Industries and Celltrion have established a successful collaboration to develop biosimilar versions of key biologic drugs. This partnership has enabled both companies to expand their biosimilars portfolios and reach a wider patient population.
17. Boehringer Ingelheim and AbbVie – Boehringer Ingelheim and AbbVie have partnered to develop and commercialize biosimilars for multiple indications, such as rheumatoid arthritis and psoriasis. This collaboration has enabled both companies to enhance their biosimilars pipelines and compete more effectively in the market.
18. Merck & Co. and Samsung Bioepis – Merck & Co. and Samsung Bioepis have joined forces to develop and market biosimilars for global markets. This collaboration has enabled both companies to expand their biosimilars portfolios and provide affordable treatment options to patients.
19. Fresenius Kabi and mAbxience – Fresenius Kabi and mAbxience have collaborated on the development and production of biosimilar versions of several blockbuster drugs. This collaboration has helped both companies expand their presence in the biosimilars market.
20. Lupin and Mylan – Lupin and Mylan have partnered to develop and commercialize biosimilar versions of several biologic drugs. This partnership has allowed both companies to leverage their expertise and resources to bring high-quality biosimilars to market.
Insights:
The biosimilars market is expected to witness continued growth in the coming years, driven by increasing demand for affordable biologic drugs. As more companies enter into collaborations to develop biosimilars, competition in the market is likely to intensify. Additionally, regulatory approvals and market access strategies will play a crucial role in determining the success of biosimilars collaborations. Overall, the future looks promising for the biosimilars market, with opportunities for innovation and expansion on the horizon. By staying informed about the top collaboration deals in the industry, pharmaceutical professionals can gain valuable insights into market trends and make informed decisions about their business strategies.
Related Analysis: View Previous Industry Report
